New York City-based Icahn School of Medicine at Mount Sinai is partnering with HeartBeam, a medical technology company, to develop and validate a new AI-electrocardiogram algorithm.
HeartBeam’s flagship product is its 12-lead ECG home monitoring system, which includes synthesis software and a portable recorder. The device measures from three non-coplanar dimensions the heart’s electrical activity — data which has historically been inaccessible to AI development, according to a March 10 company news release.
Mount Sinai and HeartBeam are collaborating to create and train an AI model that uses the 12-lead ECG. Together, they will develop personalized algorithms that would include patient wellness insights, condition-focused assessments, and applications for chronic condition management.
“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems,” Joshua Lampert, MD, medical director of machine learning for Mount Sinai Fuster Heart Hospital and director of cardiovascular artificial intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai, said in the release.
“Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional health care settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs,” Dr. Lampert said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
